CrossrefInfokarte
Adjuvant Therapy Combining Donafenib and Sintilimab Enhances Recurrence‐Free Survival in Hepatocellular Carcinoma Patients With High‐Risk Recurrence Factors After Radical Resection: A Retrospective Cohort Study
MedComm – Oncology · 2025-03 · 4 (1)
DOI: 10.1002/mog2.70013 ↗Abstract
Kein Abstract verfügbar.
EUVIMED